News | December 31, 2014

Reva Implants First Patients With Fantom Bioresorbable Stent

Scaffold designed to restore blood flow to keep heart vessel open during healing, then disappear over a period of time restoring natural function of the artery

stents, bioresorbable, clinical trial, clinical study

Image courtesy of Reva

December 31, 2014 — Reva Medical initiated patient enrollment with its Fantom bioresorbable drug-eluting scaffold. The first patient implants were performed by Alexandre Abizaid, M.D., director of Invasive Cardiology at Institute Dante Pazzanese of Cardiology in Sao Paulo, Brazil. Abizaid is co-principal investigator for the Fantom clinical trial program. Jeff Anderson, Reva's senior vice president of Clinical and Regulatory Affairs, as in previous clinical studies, was present for the implants. "The scaffold was easily delivered and the procedure was aided by the visibility of the scaffold under X-ray, a feature that we believe provides physicians with a valuable tool for confirming proper placement during implant," says Anderson.

Fantom is a fully bioresorbable sirolimus-eluting coronary scaffold that is designed to dissolve over time, leaving the artery free of a permanent implant and thereby allowing the artery to return to its vasomotion. Fantom is made from Reva's proprietary polymer that was developed specifically for scaffold performance. The properties of Reva's polymer provide for excellent scaffold strength in a thin-strut design, ease-of-use features like single-step inflation and complete visibility of the scaffold under X-ray, an attribute unique to Reva among bioresorbable scaffolds.

For more information: www.teamreva.com

Related Content

Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Clinical Study | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Clinical Study | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Clinical Study | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Clinical Study | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init